Nottingham-defined mitotic score: Comparison with visual and image cytometric phosphohistone H3 labeling indices and correlation with oncotype DX recurrence score

Applied Immunohistochemistry and Molecular Morphology

Volumn 21, Issue 1, 2013, Pages 48-53

  Zbytek, Blazej ^a,b   Cohen, Cynthia ^b   Wang, Jason ^b   Page, Andrew ^b   Williams, Daron J ^c   Adams, Amy L ^b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

breast; mitoses; Oncotype DX RS; phosphohistone H3

Indexed keywords

HISTONE H3; PHOSPHOHISTONE H3; UNCLASSIFIED DRUG;

ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; CONTROLLED STUDY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; HEMATOXYLIN AND EOSIN MITOTIC SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MITOSIS; ONCOTYPE DX RECURRENCE SCORE; PRIORITY JOURNAL; SCORING SYSTEM; TISSUE SECTION;

BREAST NEOPLASMS; CELL PROLIFERATION; FEMALE; HISTONES; HUMANS; IMAGE CYTOMETRY; IMMUNOHISTOCHEMISTRY; MITOSIS; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; RECEPTORS, ESTROGEN; RESEARCH DESIGN; TUMOR MARKERS, BIOLOGICAL;

EID: 84871982967     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e3182427cda     Document Type: Article

References (21)

1. U.S. Breast Cancer Statistics [Breastcancer.org website]. Available at: http://www.breastcancer.org/symptoms/understand-bc/statistics. jsp. Accessed April 19, 2011.
2. Pathology Reporting of Breast Disease. A joint document incorporating the third edition of the NHS Breast Screening Programme's Guidelines for Pathology Reporting in Breast Cancer Screening and the second edition of The Royal College of Pathologists' Minimum Dataset for Breast Cancer Histopathology [NHSBSP website]. NHSBSAP Publication No 58. Available at: http:/cancerscreening.nhs.uk/ breastscreen/publications/nhsbsp58.html NHS Cancer Screening Programmes and The Royal College of Pathologists. Accessed December 2011.
3. Hall PA, Levison DA. Review: assessment of cell proliferation in histological material. J Clin Pathol. 1990;43:184-192. (Pubitemid 20087565)
4. Hendzel MJ, Wei Y, Mancini MA, et al. Mitosis-specific phosphor-ylation of histone H3 initiates primarily within pericentromeric heterochromatin during G2 and spreads in an ordered fashion coincident with mitotic chromosome condensation. Chromosoma. 1997;106:348-360. (Pubitemid 27510848)
5. Bossard C, Jarry A, Colombeix C, et al. Phosphohistone H3 labelling for histoprognostic grading of breast adenocarcinomas and computer-assisted determination of mitotic index. J Clin Pathol. 2006;59:706-710. (Pubitemid 44048778)
6. Williams DJ, Cohen C, Darrow M, et al. Proliferation (Ki-67 and phosphohistone H3) and oncotype DX recurrence score in estrogen receptor-positive breast cancer. Appl Immunohistochem Mol Morphol. 2011;19:431-436.
7. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817-2826. (Pubitemid 40051905)
8. Skaland I, Janssen EA, Gudlaugsson E, et al. Phosphohistone H3 expression has much stronger prognostic value than classical prognosticators in invasive lymph node-negative breast cancer patients less than 55 years of age. Mod Pathol. 2007;20: 1307-1315. (Pubitemid 350126856)
9. Gerdes J, Lemke H, Baisch H, et al. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984;133:1710-1715. (Pubitemid 14035254)
10. Brenner RM, Slayden OD, Rodgers WH, et al. Immunocytochem-ical assessment of mitotic activity with an antibody to phosphory-lated histone H3 in the macaque and human endometrium. Hum Reprod. 2003;18:1185-1193. (Pubitemid 36740562)
11. Juan G, Traganos F, Darzynkiewicz Z. Histone H3 phosphorylation in human monocytes and during HL-60 cell differentiation. Exp Cell Res. 1999;246:212-220. (Pubitemid 29393761)
12. Ribalta T, McCutcheon IE, Aldape KD, et al. The mitosis-specific antibody anti-phosphohistone-H3 (PHH3) facilitates rapid reliable grading of meningiomas according to WHO 2000 criteria. Am J Surg Pathol. 2004;28:1532-1536. (Pubitemid 39425522)
13. Takei H, Bhattacharjee MB, Rivera A, et al. New immunohisto-chemical markers in the evaluation of central nervous system tumors: a review of 7 selected adult and pediatric brain tumors. Arch Pathol Lab Med. 2007;131:234-241.
14. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24:3726-3734. (Pubitemid 46622311)
15. Flanagan MB, Dabbs DJ, Brufsky AM, et al. Histopathologic variables predict Oncotype DX recurrence score. Mod Pathol. 2008;21:1255-1261.
16. Auerbach J, Kim M, Fineberg S. Can features evaluated in the routine pathologic assessment of lymph node-negative estrogen receptor-positive stage I or II invasive breast cancer be used to predict the Oncotype DX recurrence score? Arch Pathol Lab Med. 2010;134:1697-1701.
17. Allison KH, Kandalaft PL, Sitlani CM, et al. Routine pathologic parameters can predict Oncotype DX(TM) recurrence scores in subsets of ER positive patients: who does not always need testing? Breast Cancer Res Treat. 2011. [Epub ahead of print].
18. Geradts J, Bean SM, Bentley RC, et al. The oncotype DX recurrence score is correlated with a composite index including routinely reported pathobiologic features. Cancer Invest. 2010;28:969-977.
19. Yorozuya K, Takeuchi T, Yoshida M, et al. Evaluation of oncotype DX recurrence score as a prognostic factor in Japanese women with estrogen receptor-positive, node-negative primary Stage I or IIA breast cancer. J Cancer Res Clin Oncol. 2010;136:939-944.
20. The TAILORz Breast Cancer Trial [NCI website]. Available at: http://www.cancer.org/clinicaltrials/noteworthy-trials/tailorx. Accessed October 22, 2010.
21. Kelly CM, Krishnamurthy S, Bianchini G, et al. Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers. Cancer. 2010;116:5161-5167.